Ligands for cereblon: 2017–2021 patent overview

References

• Higgins JJ, Pucilowska J, Lombardi RQ, et al. A mutation in a novel ATP-dependent Lon protease gene in a kindred with mild mental retardation. Neurology. 2004;63(10):1927–1931.
   PubMed Web of Science ®Google Scholar
• Chang XB, Stewart AK. What is the functional role of the thalidomide binding protein cereblon. Int J Biochem Mol Biol. 2011;2:287–294.
   PubMedGoogle Scholar
• Shi Q, Chen L. Cereblon: a protein crucial to the multiple functions of immunomodulatory drugs as well as cell metabolism and disease generation. J Immunol Res. 2017;2017:9130608.
   PubMed Web of Science ®Google Scholar
• Sperling AS, Burgess M, Keshishian H, et al. Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs. Blood. 2019;134(2):160–170.
   PubMed Web of Science ®Google Scholar
• Zhihua H, Vierstra RD. The cullin-RING ubiquitin-protein ligases. Annu Rev Plant Biol. 2011;62(1):299–334.
   PubMedGoogle Scholar
• Higgins JJ, Hao J, Kosofsky BE, et al. Dysregulation of large-conductance Ca2+-activated K+ channel expression in nonsyndromal mental retardation due to a cereblon p.R419X mutation. Neurogenetics. 2008;9(3):219–223.
   PubMed Web of Science ®Google Scholar
• Kim HK, Ko TH, Nyamaa B, et al. Cereblon in health and disease. Pflugers Archiv. 2016; 468(8) 1299–1309.
   PubMed Web of Science ®Google Scholar
• Ito T, Ando H, Suzuki T, et al., Identification of a primary target of thalidomide teratogenicity. Science. 327(5971): 1345–1350. 2010.
   PubMed Web of Science ®Google Scholar
• Moon AM, Capecchi MR. Fgf8 is required for outgrowth and patterning of the limbs. Nat Genet. 2000;26(4):455–459.
   PubMed Web of Science ®Google Scholar
• Raje N, Hideshima T, Anderson KC. Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma. Expert Rev Anticancer Ther. 2006;6(9):1239–1247.
   PubMed Web of Science ®Google Scholar
• Sato T, Ito T, Handa H. Cereblon-based small-molecule compounds to control neural stem cell proliferation in regenerative medicine. Front Cell Dev Biol. 2021;11. https://doi.org/10.3389/fcell.2021.629326
   Google Scholar
• Ito T, Handa H. Molecular mechanisms of thalidomide and its derivatives. Proc Jpn Acad Ser B Phys Biol Sci. 2020;96(6):189–203.
   PubMed Web of Science ®Google Scholar
• Hansen JD, Correa M, Nagy MA, et al., Discovery of CRBN E3 Ligase modulator CC-92480 for the treatment of relapsed and refractory multiple myeloma. J Med Chem. 63(13): 6648–6676. 2020.
   PubMed Web of Science ®Google Scholar
• Girardinia M, Maniacia C, Hughesa CJ, et al. Cereblon versus VHL: hijacking E3 ligases against each other using PROTACs. Bioorg Med Chem. 2019;27(12):2466–2479.
   PubMed Web of Science ®Google Scholar
• Jang J, To C, De Clercq DJH, et al. Mutant-selective allosteric egfr degraders are effective against a broad range of drug-resistant mutations. Angew Chem Int Ed. 2020;59(34):14481–14489.
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhao H-Y, Xi -X-X, et al. Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC). Eur J Med Chem. 2020;189:112061.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Chang X, Zhang C, et al. Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1). J Enzyme Inhib Med Chem. 2020;35(1):1606–1615.
   PubMed Web of Science ®Google Scholar
• Yang K, Zhao Y, Nie X, et al. A cell-based target engagement assay for the identification of cereblon e3 ubiquitin ligase ligands and their application in HDAC6 degraders. Cell Chem Biol. 2020;27(7):1–11.
   PubMed Web of Science ®Google Scholar
• Li Y, Yang J, Aguilar A, et al. Discovery of MD-224 as a first-in-class, highly potent, and efficacious proteolysis targeting chimera murine double minute 2 degrader capable of achieving complete and durable tumor regression. J Med Chem. 2019;62(2):448–466.
   PubMed Web of Science ®Google Scholar
• Steinebach C, Lindner S, Udeshi ND, et al. Homo-PROTACs for the chemical knockdown of cereblon. ACS Chem Biol. 2018;13(9):2771–2782.
   PubMed Web of Science ®Google Scholar
• Thalidomide Monograph for Professionals. [cited 28 Aug 2021]. Drugs.com
   Google Scholar
• Pomalidomide Monograph for Professionals. [cited 28 Aug 2021]. Drugs.com
   Google Scholar
• Lenalidomide Monograph for Professionals. [cited 28 Aug 2021]. Drugs.com
   Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT03374085. Retrieved 28 Aug 2021.
   Google Scholar
• Halford B Arvinas unveils PROTAC structures. . Chem Eng News. 2021;99:5.
   Web of Science ®Google Scholar
• Luzzio FA, Figg WD. Thalidomide analogues: derivatives of an orphan drug with diverse biological activity. Expert Opin Ther Pat. 2004;14(2):215–229.
   Web of Science ®Google Scholar
• Phillips AJ, Nasveschuk CG, Henderson JA, et al. N/O-Linked degrons and degronimers for protein degradation. WO2018237026. 2018;
   Google Scholar
• Crew AP, Crews CM, Dong H, et al. Cereblon ligands and bifunctional compounds comprising the same. WO 2019199816. 2019;
   Google Scholar
• Gray N, Zhang T, Fischer E, et al. Immunomodulatory compounds. WO2020006233. 2020;
   Google Scholar
• Gray N, Zhang T, Fischer E, et al. Bispecific degraders. WO2020006265. 2020;
   Google Scholar
• Gray N, Zhang T, Yang P, et al. Degraders of hepatitis C virus NS3/4a protein. WO 2020069125. 2020;
   Google Scholar
• Gray N, Zhang T, Fischer E, et al. New CRBN modulators. WO 2020006262. 2020;
   Google Scholar
• Ruppel SK, Yang Z, Lowe JT, et al. Compounds and uses thereof. WO 2020160196. 2020;
   Google Scholar
• Ruppel SK, Yang Z, Lowe H, et al. Compounds and uses thereof. WO 2020160198. 2020;
   Google Scholar
• Mainolfi N, Ji N, Kluge AF, et al. IRAK degraders and uses thereof. WO 2020113233. 2020;
   Google Scholar
• Crew AP, Berlin M, Dong H, et al. Cereblon ligands and bifunctional compounds comprising the same. US 20180215731. 2018;
   Google Scholar
• Ji N, Kluge AF, Weiss M, et al., Tricyclic CRBN ligands and uses thereof. WO 2020010177. 2020;
   Google Scholar
• Phillips AJ, Nasveschuk CG, Henderson JA, et al. Amine-linked c3-glutarimide degronimers for target protein degradation. WO 2017197051. 2017;
   Google Scholar
• Phillips AJ, Nasveschuk CG, Henderson JA, et al. Degraders and degrons for targeted protein degradation. WO 2019099868. 2019;
   Google Scholar
• Mainolfi N, Ji N, Kluge AF, CRBN ligands and uses thereof. WO 2019140387. 2019;
   Google Scholar
• Nasveschuk CG, Norcross R, Dey F, et al. Heterocyclic compounds for medical treatment. WO 2020181232. 2020;
   Google Scholar
• Nasveschuk CG, Dey F, Goergler A, et al. Spirocyclic compounds. WO 2019204354. 2020;
   Google Scholar
• Backus KM, Correia BE, Lum KM, et al. Proteome-wide covalent ligand discovery in native biological systems. Nature. 2016;534(7608):570–574.
   PubMed Web of Science ®Google Scholar
• Cravatt BF, Patricelli M, Stamos D, et al. Cereblon modulators and uses thereof. US20200206201. 2020;
   Google Scholar
• Dey F, Goergler A, Norcross R, et al. Spirocyclic compounds. WO 2019236483. 2019;
   Google Scholar
• Ji N, Sintchak MD, Zhang Y, et al., Fused-glutarimide CRBN ligands and uses thereof. WO 2021011631. 2021;
   Google Scholar
• Hansen JD, Condroski K, Correa M, et al. Protein degradation via CRL4CRBN ubiquitin ligase: discovery and structure–activity relationships of novel glutarimide analogs that promote degradation of aiolos and/or GSPT1. J Med Chem. 2018;61(2):492–503.
   PubMed Web of Science ®Google Scholar
• Xiao D, Wang Y-J, Wang H-L, et al. Design and synthesis of new lenalidomide analogs via Suzuki cross-coupling reaction. Arch Pharm. 2020;353(7):1900376.
   Web of Science ®Google Scholar
• Heim C, Pliatsika D, Mousavizadeh F, et al. De-novo design of cereblon (CRBN) effectors guided by natural hydrolysis products of thalidomide derivatives. J Med Chem. 2019;62(14):6615–6629.
   PubMed Web of Science ®Google Scholar
• Burslem GM, Ottis P, Jaime-Figueroa S, et al. Efficient synthesis of immunomodulatory drug analogues enables exploration of structure–degradation relationships. ChemMedChem. 2018;13(15):1508–1512.
   PubMed Web of Science ®Google Scholar
• Hartmann MD, Boichenko I, and Coles M et al. Thalidomide mimics uridine binding to an aromatic cage in cereblon. et al. J Struct Biol. 2014;188(3):225–232.
   PubMed Web of Science ®Google Scholar
• Boichenko I, Bär K, and Deiss S et al. Chemical Ligand Space of Cereblon. et al. ACS Omega. 2018;3(9):11163–11171.
   PubMed Web of Science ®Google Scholar